Venolife Duo, 500 mg 30 pcs

Pharmacotherapeutic group: Venotonizing and venoprotective agent.

CodeATH: C05СА53

Pharmacological properties

Pharmacodynamics

The combination of diosmin + hesperidin has venotonizing and angioprotective properties. The drug reduces venous distensibility and venous stasis, decreases capillary permeability and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug with respect to the indices of venous hemodynamics. Statistically reliable dose-dependent effect of the drug was demonstrated for the following venous plethysmographic parameters: venous capacity, venous distensibility, venous emptying time. An optimal dose-effect ratio is observed when taking 1000 mg per day.

The combination of diosmin + hesperidin increases venous tone: venous occlusion plethysmography showed a decrease in venous emptying time. In patients with signs of severe microcirculatory disorders, after therapy with the drug there was (statistically significant in comparison with placebo) an increase of capillary resistance evaluated by angiostereometry.

Pharmacokinetics

The main excretion of the drug is in the feces. With urine, on average, about 14% of the administered amount of the drug is excreted. The half-life period of the drug is 11 hours.

The drug undergoes active metabolism, which is confirmed by the presence of phenolic acids in urine.

Indications

Venolife Duo is indicated for the treatment of symptoms of chronic venous diseases (elimination and relief of symptoms).

Treatment of symptoms of venous-lymphatic insufficiency:

– pain;

– spasms of the lower extremities;

– feeling of heaviness and fullness in the legs;

– “fatigue” of the legs.

Treatment of manifestations of venous-lymphatic insufficiency:

– swelling of the lower extremities;

– trophic changes in the skin and subcutaneous tissue;

– venous trophic ulcers.

Symptomatic treatment of acute and chronic hemorrhoids.

Pharmacological effect

Pharmacotherapeutic group: Venotonic and venoprotective agent.

CodeATX: C05CA53

Pharmacological properties

Pharmacodynamics

The combination of diosmin + hesperidin has venotonic and angioprotective properties. The drug reduces the distensibility of veins and venous stagnation, reduces capillary permeability and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug in relation to indicators of venous hemodynamics. A statistically significant dose-dependent effect of the drug was demonstrated for the following venous plethysmographic parameters: venous capacity, venous distensibility, venous emptying time. The optimal dose-effect ratio is observed when taking 1000 mg per day.

The combination of diosmin + hesperidin increases venous tone: using venous occlusion plethysmography, a decrease in venous emptying time was shown. In patients with signs of severe microcirculation disorders, after treatment with the drug there was a (statistically significant compared to placebo) increase in capillary resistance, assessed by angiostereometry.

The therapeutic effectiveness of the combination of diosmin + hesperidin has been proven in the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids.

Pharmacokinetics

The main excretion of the drug occurs in the feces. On average, about 14% of the administered amount of the drug is excreted in the urine. The half-life is 11 hours.

The drug undergoes active metabolism, which is confirmed by the presence of phenolic acids in the urine.

Special instructions

Before you start taking Venolife Duo, it is recommended to consult your doctor.

In case of exacerbation of hemorrhoids, the prescription of Venolife Duo does not replace the specific treatment of other anal disorders. The duration of treatment should not exceed the periods specified in the section “Method of administration and dosage”. If the symptoms do not disappear after the recommended course of therapy, you should be examined by a proctologist who will select further therapy.

In the presence of venous circulation disorders, the maximum effect of treatment is ensured by a combination of therapy with a healthy (balanced) lifestyle: it is advisable to avoid prolonged exposure to the sun, prolonged standing on your feet, and also,

Reducing excess body weight is recommended. Walking and, in some cases, wearing special stockings help improve blood circulation.

Contact your doctor immediately if your condition worsens or does not improve during treatment.

Impact on the ability to drive vehicles and machinery

Clinical studies have not been conducted to study the effect of the combination of diosmin + hesperidin on the ability to drive a car and perform work that requires a high speed of mental and physical reactions. However, based on the available safety data, it can be concluded that diosmin + hesperidin do not affect (do not have a significant effect) on these processes.

Active ingredient

Purified micronized flavonoid fraction (diosmin, flavonoids in terms of hesperidin)

Composition

One tablet contains:

active ingredient:

Purified micronized flavonoid fraction (calculated as anhydrous substance),

containing diosmin (90%) and other flavonoids (10%) – 500 mg or 1000 mg.

excipients:

gelatin,

magnesium stearate,

microcrystalline cellulose,

sodium carboxymethyl starch,

talc.

Film casing:

ready-mix “Vivacoat” [macrogol 6000, titanium dioxide, glycerol, magnesium stearate, hypromellose, red iron oxide dye, yellow iron oxide dye],
sodium lauryl sulfate.

Pregnancy

Pregnancy

Experiments on animals did not reveal teratogenic effects.

To date, there have been no reports of undesirable effects when using the drug by pregnant women.

Breastfeeding

Due to the lack of data regarding the excretion of the drug in breast milk, taking the drug is not recommended for nursing women.

Effect on reproductive function

Reproductive toxicity studies have not shown
influence on reproductive function in rats of both sexes.

Contraindications

Hypersensitivity to the active substance or to the excipients included in the drug.

Not
It is recommended to take the drug for breastfeeding women.

Side Effects

Side effects of the diosmin + hesperidin combination observed during clinical studies were mild. Disorders from the gastrointestinal tract (diarrhea, dyspepsia, nausea, vomiting) were predominantly observed.

While taking the combination of diosmin + hesperidin, the following side effects were reported, in the following gradation: very often (≥1/10); often (≥1/100,<1/10); uncommon (≥1/1,000, <1/100); rare (≥1/10,000, <1/1,000); extremely rare (< 1/10,000), unspecified frequency (frequency cannot be calculated from available data).

From the central nervous system:

Rarely: dizziness, headache, general malaise.

From the gastrointestinal tract:

Common: diarrhea, dyspepsia, nausea, vomiting.

Uncommon: colitis.

Unspecified frequency: abdominal pain.

From the skin:

Rarely: skin rash, itching, urticaria.

Unspecified frequency: isolated swelling of the face, lips, eyelids. In exceptional cases, angioedema.

Inform your doctor if you develop any
including adverse reactions not mentioned in this instruction, as well as
changes in laboratory parameters during therapy.

Interaction

Clinical studies have not been conducted to study the interactions of the combination of diosmin + hesperidins with other drugs.

No cases have been reported to date
drug interactions.

Overdose

No cases of overdose have been described.

In case of drug overdose, seek medical help immediately.

Storage conditions

At a temperature not exceeding 25 °C.

Store in
out of the reach of children.

Shelf life

2 years.

Manufacturer

Akrikhin JSC, Russia